Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Severe and fatal liver injury connected to latent TB treatment

The CDC has investigated reports of 21 patients who were hospitalized because of severe liver injury associated with a two-month treatment regimen of rifampin and pyrazinamide (RIF-PZA) for latent TB infection.

News image

fiogf49gjkf04

Of the 21 patients, 16 recovered and 5 died.

Findings from the investigations into these cases are included in the 31 August edition of the Centers for Disease Control and Prevention's (CDC's) Morbidity and Mortality Weekly Report (MMWR).

As a result, CDC and the American Thoracic Society are issuing revised treatment guidelines for latent tuberculosis infection (LTBI). These are to limit the circumstances in which the combination of RIF-PZA is prescribed, and to strengthen the level of patient counseling and monitoring recommended for LTBI treatment regimens.

For most individuals with LTBI, the new guidelines recommend the 9-month regimen of daily isoniazid (INH) as the preferred treatment.

CDC recommends providers use RIF-PZA with caution, especially in those currently taking other medications that have been associated with liver injury. Care should also be taken with alcoholic subjects, even if alcohol usage is discontinued during treatment.

However, with careful clinical and laboratory monitoring, as outlined in the recommendations, RIF-PZA remains an option for patients at high risk of developing active TB disease and who are unlikely to complete a 9-month regimen of isoniazid (INH).

For HIV-negative individuals with LTBI, the new guidelines recommend the 9-month regimen of daily INH as the standard treatment.

While available data do not suggest excessive risk of severe side-effects associated with RIF-PZA among HIV-positive individuals, providers should consider the use of INH when completion of this longer regimen can be assured.

Rifampin and pyrazinamide used with caution in those already at increased liver damage risk.
Centers for Disease Control and Prevention
The guidelines emphasize TB testing and treatment for people at high risk.

Those at high risk of developing active TB include individuals with LTBI who are HIV-infected, those who were recent contacts of someone with active TB, and injection drug users. Residents or employees of high-risk congregate settings are also at increased risk.

Furthermore, providers are reminded that treatment is recommended for foreign-born people with LTBI, who have lived in the United States for less than 5 years and who were born in countries with high rates of TB.

After 5 years, treatment decisions should be made on the same basis as other patients.

As all regimens for treating LTBI have been associated with liver injury, careful monitoring during treatment is important to avoid severe damage.

Any additional cases of severe liver damage associated with treatment of LTBI should be reported to the CDC's Division of TB Elimination, they add.

Centers for Disease Control and Prevention
11 September 2001

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us